Can a malaria drug help kids with rare lung disease?

NCT ID NCT04532346

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether hydroxychloroquine, a drug used for malaria and arthritis, can safely improve breathing in children with interstitial lung disease caused by genetic mutations. Researchers will enroll 60 children and randomly assign them to receive the drug or not, measuring oxygen levels and breathing rates. The goal is to see if the drug reduces symptoms like coughing and breathing difficulty.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
hydroxychloroquine
What this could lead to
If it works, this could point toward a treatment to improve breathing and reduce symptoms in children with genetic lung disease.
What could go wrong
This is a very early, small trial (60 children) with no guarantee of success. Hydroxychloroquine may not work for these rare conditions and could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHILDREN'S INTERSTITIAL LUNG DISEASE WITH GENETIC CAUSES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Children's hospital of Fudan University

    RECRUITING

    Shanghai, Shanghai Municipality, 201102, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.